title: Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation.
abstract: BACKGROUND
  Elevation of pulmonary vascular resistance (PVR) has been considered to predict a bad outcome after orthotopic heart transplantation (HTx). A transpulmonary gradient (TG) > or =15 mmHg and PVR > or =5 wood (w) are correlated with a three-fold increase in 2-days as well as 30-days and 6-, 12-month mortality.
  
  
  METHODS
  We performed a retrospective analysis of 400 consecutive transplanted patients (pts) on hemodynamic data over a time period of 3.5 years. In 83 pts (23%) preoperative PVR was > or =5 w and TG >15 mmHg. Vasodilator studies were performed in this group of pts in order to evaluate pulmonary vasoreactivity or hemodynamic improvement.
  
  
  RESULTS
  Hemodynamic follow-up post-transplantation showed a significant (p<0.001) decrease in mean TG to 8.8 mmHg within the first, 7.7 after the fifth year as well as decrease in PVR from 5.5 to 1.6, within the first and fifth year post-transplantation. Compared to the control group (n=286) (re-transplants n=6 and pediatric pts n=25 excluded) pts with TG <15 mmHg and/or PVR <5 w, transplanted within the same period, 30-day mortality and cumulative survival after 1 and 5 years do not show any significant difference with a mortality of 3%, 22% and 33% (p<0.05). Subgroup analysis for pts with endstage of ischemic versus dilatative cardiomyopathy has not shown any significant difference in mortality.
  
  
  CONCLUSIONS
  In a retrospective analysis of 400 pts elevated PVR does not predict a bad outcome after orthotopic heart transplantation in early and late mortality.
authors.affiliation: Department of Cardiovascular Surgery, Heart Center North Rhine-Westphalia, University of Bochum, Bad Oeynhausen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Tenderich
authors.forename: M M
authors.initials: MM
authors.lastname: Koerner
authors.forename: B
authors.initials: B
authors.lastname: Stuettgen
authors.forename: N
authors.initials: N
authors.lastname: Mirow
authors.forename: L
authors.initials: L
authors.lastname: Arusoglu
authors.forename: M
authors.initials: M
authors.lastname: Morshuis
authors.forename: A
authors.initials: A
authors.lastname: Bairaktaris
authors.forename: K
authors.initials: K
authors.lastname: Minami
authors.forename: R
authors.initials: R
authors.lastname: Koerfer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000601:surgery; D016027:Heart Transplantation / Q000401:mortality / Q000502:physiology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D012189:Retrospective Studies; D015996:Survival Rate; D014019:Tissue Donors; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents